摘要
支气管哮喘是涉及多种细胞及细胞因子的慢性气道炎症性疾病。目前吸入型糖皮质激素、β_2受体激动剂、茶碱和白三烯受体拮抗剂等多种哮喘治疗药物均在临床广泛使用,但部分患者的哮喘症状仍不能得到良好控制。白介素(IL)-9参与哮喘的发生发展,抗IL-9单克隆抗体有望成为一种新的哮喘治疗药物。
Bronchial asthma is a chronic airway inflammatory disease involving many types of cells and cytokines. Currently, inhaled glucocorticoids, β2 receptor agonists, theophylline, leukotriene receptor antagonists are widely used in clinical. However, in some patients these treatments are still not able to control asthma symptoms sufficiently. Since IL-9 is involved in pathogenic aspects of asthma, the anti-interleukin-9 monoclonal antibody would be expected to be a newer treatment for asthma. This review focuses on the progress about it, especially MEDI-528 in asthma treatment.
出处
《世界临床药物》
CAS
2010年第1期11-14,共4页
World Clinical Drug
